Monthly Archives: September 2010

MedImmune Bets Its Fate on “Biobetters”

AstraZeneca’s biologics shop makes a decisive move in the biosimilars market. MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were […]
Posted in Biotech, Deals, Global, R&D, Strategy | Tagged , , , , , , | 1 Comment

Pfizer and American Kennel Club Team Up For New Research

Pfizer’s Animal Health unit has signed an exclusive deal with the American Kennel Club’s Canine Health Foundation (CHF)—the largest nonprofit worldwide—to fund health research exclusively for canines. This new research partnership names Pfizer Animal Health the sole biopharmaceutical partner of CHF, and begins with Pfizer committing to provide an initial $50,000 over a two-year period. […]
Posted in Deals | Tagged , | Leave a comment

Is M-health Just for M-people?

Jacky Law asks who is really being served as medicine adapts to an increasingly mobile, connected and interactive world? If m-health advocates are to be believed, more than a fifth of all medicine will be practised online by 2013 and much of that will be by phone. Peter Wagemann, vice-president of mHealth Initiative, goes further, […]
Posted in Europe, Global, Guest Blog, Technology | Tagged , , , , , | 1 Comment

How Do We Raise R&D Productivity?

That’s the big question that no one has answered yet. So perhaps its worth breaking it down into smaller parts, suggests Dr Brian D Smith. An ill-posed question is a mathematician’s term that well describes what many Big Pharma companies are asking themselves, namely, how can we raise R&D productivity? It’s ill-posed because it has […]
Posted in Europe, Global, Guest Blog, Marketing, Strategy | Tagged , , , | Leave a comment

Pfizer Adds FoldRx to its Specialty Care Unit

Pfizer on Wednesday announced that it acquired a small rare-disease drug firm, FoldRx, for an undisclosed sum of money. Pfizer spokeswoman Gwen Fischer told Pharm Exec that the deal came together in a matter of weeks, and that FoldRx will be fully incorporated into Pfizer’s research division. All of FoldRx’s employees are expected to become […]
Posted in Deals, Strategy | Tagged , , | Leave a comment
  • Categories

  • Meta